Evidence map›Paper›PMID 34944935›Full record

ArticleCancers2021

Reirradiation for Nasal Cavity or Paranasal Sinus Tumor-A Multi-Institutional Study.

Hideya Yamazaki, Gen Suzuki, Norihiro Aibe, Makoto Yasuda, Hiroya Shiomi, Ryoong-Jin Oh, Ken Yoshida, Satoaki Nakamura, Koji Konishi, Mikio Ogita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hideya YamazakiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Gen SuzukiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.ORCID 0000-0001-6018-468X
Norihiro AibeDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.ORCID 0000-0002-6595-0205
Makoto YasudaDepartment of Otolaryngology-Head and Neck Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajiicho Kawaramachi Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.ORCID 0000-0002-4340-9338
Hiroya ShiomiCyberKnife Center, Soseikai General Hospital, Kyoto 612-8473, Japan.
Ryoong-Jin OhDepartment of Radiation Oncology, Miyakojima IGRT Clinic, Osaka 534-0021, Japan.ORCID 0000-0002-7633-0669
Ken YoshidaDepartment of Radiology, Kansai Medical University, Hirakata 573-1191, Japan.
Satoaki NakamuraDepartment of Radiology, Kansai Medical University, Hirakata 573-1191, Japan.
Koji KonishiDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Mikio OgitaRadiotherapy Department, Fujimoto Hayasuzu Hospital, Miyakonojo 885-0055, Japan.
Kyoto Prefectural University of Medicine · JPKajima Corporation (Japan) · JPKansai Medical University · JPOsaka International Cancer Institute · JP

Funding

JASTRO not vailable
6 · The paper itself

Abstract

We evaluated the efficacy and toxicity of reirradiation of nasal cavity or paranasal sinus tumors. We collected and analyzed multi-institutional data of reirradiation cases. Seventy-eight patients with nasal or paranasal sinus tumors underwent reirradiation. The median survival time was 20 months with a medial follow-up of 10.7 months. The 2-year local control and overall survival rates were 43% and 44%, respectively. Tumor volume (≤25 cm

Indexed as

nasal cavity and paranasal sinusoptic pathwayreirradiation

Identifiers

PMID34944935
PMCPMC8699758
OpenAlexW4200529178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.